PO.ET05.02 · 实验与分子治疗

TROP2靶向抗体药物偶联物datopotamab deruxtecan(Dato-DXd)在乳腺癌细胞系中与DNA损伤反应相关的抗肿瘤作用

Antitumor effect of TROP2-targeted antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), in association with DNA damage response in breast cancer cell lines

海报缩略图:TROP2靶向抗体药物偶联物datopotamab deruxtecan(Dato-DXd)在乳腺癌细胞系中与DNA损伤反应相关的抗肿瘤作用
编号 2943 展板 20 时间 4/20 02:00–05:00 区域 Section 11 主讲 Sujin Ham, BS
分会场 Cellular Responses to Anticancer Drugs
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Seohyeon Lim1, Sujin Ham1, Hae Min Hwang1, Youlim Noh1, Jiwon Koh2, Chaeyoung Lee1, Minyoung Jeong1, Yu-Jin Kim3, Minyoung Lee4, Sohyeon Kim4, Changhee Park5, Dae-Won Lee5, Kyung-Hun Lee5, Seock-Ah Im5

1Cancer Biology, Graduate School of Interdisciplinary Graduate Program & Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of,2Department of Pathology & Cancer Research Institute, Seoul National University Hospital & Seoul National University, Seoul, Korea, Republic of,3Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of,4Cancer Biology, Graduate School of Interdisciplinary Graduate Program, Seoul National University, Seoul, Korea, Republic of,5Department of Internal Medicine & Cancer Research Institute, Seoul National University Hospital & Seoul National University, Seoul, Korea, Republic of

摘要 Abstract

中文摘要
背景:滋养层细胞表面抗原2(TROP2),即肿瘤相关钙信号转导蛋白2(TACSTD2),是一种在多种癌症类型中表达的跨膜糖蛋白。Datopotamab deruxtecan(Dato-DXd)是一种抗体药物偶联物(ADC),由抗TROP2抗体(Datopotamab)通过可切割肽接头与拓扑异构酶I抑制剂DXd连接而成。拓扑异构酶I通过在复制和转录期间解除DNA超螺旋来维持DNA拓扑应力。我们试图确定这种传统上由拓扑异构酶I抑制剂诱导的DNA损伤机制在通过ADC递送时是否会出现,并进一步阐明Dato-DXd导致DNA损伤反应(DDR)和细胞死亡的此前未表征的分子机制。方法:本研究使用了五种已建立的人乳腺癌细胞系和一种患者来源的乳腺癌(PDC)细胞系(SNU-3171)。MCF7和SNU-3171为管腔型乳腺癌细胞系,其余为三阴性乳腺癌(TNBC)细胞系。通过集落形成测定(CFA)评估各细胞对Dato-DXd的敏感性,持续14天(0.25-5 nM)。通过流式细胞术进行内化和细胞周期分析。通过Annexin V测定检测凋亡。通过Western blotting和免疫荧光分析TROP2、DNA损伤和修复分子的蛋白表达。结果:根据CFA结果,HCC1806、HCC70和SNU-3171被确定为敏感细胞(IC50 <0.5 nM),而MCF7、MDA-MB-157和HCC1395为对Dato-DXd敏感性较低的细胞(IC50 >2.5 nM)。Dato-DXd在TROP2阳性细胞中2小时内被内化。内化后,所有TROP2阳性细胞中均形成拓扑异构酶I切割复合物(Top1ccs);然而,Top1ccs与γ-H2AX的共定位仅在敏感细胞中观察到。Dato-DXd在所有TROP2阳性细胞中诱导G2/M期阻滞。在敏感细胞中,TDP1、XRCC1、DNA连接酶III和PNKP的表达降低,而磷酸化Chk1(S345)和γ-H2AX增加,表明单链DNA损伤修复能力下降和DDR激活。此外,Dato-DXd剂量增加与更高数量的Annexin V阳性细胞和sub-G1群体相关,同时敏感细胞中裂解PARP、caspase-3和caspase-7的表达更高。结论:Dato-DXd在包括PDC在内的TROP2阳性乳腺癌细胞中表现出高效内化,并损害DNA单链断裂(SSB)修复,从而在敏感乳腺癌细胞中诱导凋亡。特别是,在大多数TROP2阳性细胞中诱导了Top1ccs的形成和G2/M期积累。需要进一步实验来阐明受损的SSB修复如何促成DNA双链断裂和凋亡的诱导。
查看英文原文 English abstract
Background: Trophoblast cell surface antigen-2 (TROP2), Tumor-associated calcium signal transducer 2 (TACSTD2) is a transmembrane glycoprotein expressed in various cancer types. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) composed of an anti-TROP2 antibody (Datopotamab) linked via a cleavable peptide linker to DXd, a Topoisomerase-I inhibitor. Topoisomerase-I maintains DNA topological stress by resolving DNA supercoils during replication and transcription. We sought to determine whether this DNA damage mechanism classically induced by topoisomerase I inhibitors emerges when delivered through an ADC, and to further elucidate the previously uncharacterized molecular mechanisms of DNA damage response (DDR) and cell death by Dato-DXd. Methods: Five established human breast cancer cell lines and one patient-derived breast cancer (PDC) cell line (SNU-3171) were used in this study. MCF7 and SNU-3171 were luminal breast cancer cell lines, and the others were triple-negative breast cancer (TNBC) cell lines. Sensitivity of each cell to Dato-DXd was assessed by colony formation assay (CFA) for 14 days (0.25-5 nM). Internalization and cell cycle analysis were performed by flow cytometry. Apoptosis was detected by Annexin V assay. The protein expression of TROP2, DNA damage, and repair molecules was analyzed by Western blotting and immunofluorescence. Results: Based on CFA results, HCC1806, HCC70, and SNU-3171 were identified as sensitive cells (IC 50 <0.5 nM), whereas MCF7, MDA-MB-157, and HCC1395 as less sensitive cells (IC 50 >2.5 nM) to Dato-DXd. Dato-DXd was internalized within 2 hours in TROP2-positive cells. Following internalization, topoisomerase-I cleavage complexes (Top1ccs) were formed in all TROP2-positive cells; however, co-localization of Top1ccs and ɣ-H2AX was observed only in sensitive cells. Dato-DXd induced G2/M arrest in all TROP2-positive cells. In sensitive cells, the expression of TDP1, XRCC1, DNA Ligase III, and PNKP was decreased, while phospho-Chk1 (S345) and ɣ-H2AX were increased, indicating a reduction in single-strand DNA damage repair capacity and activation of DDR. Moreover, increased doses of Dato-DXd were associated with higher number of Annexin V-positive cells and sub-G1 populations, as well as higher expression of cleaved PARP, caspase-3, and caspase-7 in sensitive cells. Conclusion: Dato-DXd demonstrated efficient internalization in TROP2-positive breast cancer cells including PDC, and impaired DNA single-strand break (SSB) repair, which consequently induce apoptosis in sensitive breast cancer cells. In particular, formation of Top1ccs and G2/M phase accumulation are induced in most of TROP2-positive cells. Further experiments are required to elucidate how impaired SSB repair contributes to the induction of DNA double-strand breaks and apoptosis.
利益披露 Disclosure
S. Lim, None.. S. Ham, None.. H. Hwang, None.. Y. Noh, None. J. Koh, AstraZeneza Other, Consulting fees. C. Lee, None.. M. Jeong, None.. Y. Kim, None.. M. Lee, None.. S. Kim, None.. C. Park, None.. D. Lee, None. K. Lee, Roche ). AstraZeneca Other, reported honoraria. Eisai Other, reported honoraria. Lilly Other, reported honoraria. Novartis Other, reported honoraria. Roche Other, reported honoraria. Pfizer Other, reported honoraria. S. Im, Daiichi Sankyo ), Other, Consulting fees. AstraZeneca ), Other, Consulting fees. Eisai ), Other, Consulting fees. Daewoong Pharm ). Pfizer ), Consulting fees. Roche ), Other, Consulting fees. Boryung Pharm ). Hanmi Other, Consulting fees. Lilly Other, Consulting fees. MSD Other, Consulting fees. Idience Other, Consulting fees. Norvatis Other, Consulting fees. GSK Other, Consulting fees. Bertis Other, Consulting fees.

← 返回 AACR 2026 检索